Quarterly Progress Report (Non-Cumulative)

Year   
Normalized   

Quarterly Progress Report (QPR) on age-group wise service deliveries and information on distribution of Iron and Folic Acid (IFA) syrup and tablets- Pink, Blue & Red, Albendazole tablets among the 6 focused age groups. The information is derived on the basis of data updates available from HMIS indicators (Numerator) calculated using the eligible age specific respective denominators for each age group. *The GOI quarter reporting year starts from April and ends in March of the subsequent year (Q1-April to June, Q2-July to September, Q3- October to December and Q4 January to March (of subsequent year)).

Service Delivery in Percentage

India

Children 6-59 months


Year       Q1       Q2       Q3       Q4
HMIS 9.9:
Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly)
2020-2113.113.615.514.9
HMIS 9.9:
Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly)
2019-2011.616.117.215.3
HMIS 9.9:
Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly)
2018-197.88.48.69.3
HMIS 9.9:
Percentage of children 6-59 months provided 8-10 doses (1ml) of Iron and Folic Acid (IFA) syrup (Bi weekly)
2017-186.26.47.37.0
HMIS 9.1:
Percentage of children 12-59 months provided Albendazole
2020-210.510.01.05.9
HMIS 9.1:
Percentage of children 12-59 months provided Albendazole
2019-200.74.31.01.1
HMIS 9.1:
Percentage of children 12-59 months provided Albendazole
2018-190.73.30.51.2
HMIS 9.1:
Percentage of children 12-59 months provided Albendazole
2017-180.61.90.70.9
Children 5-9 years


Year       Q1       Q2       Q3       Q4
HMIS 23.1+23.3:
Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school)
2020-2112.418.121.417.2
HMIS 23.1+23.3:
Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school)
2019-2022.734.234.718.9
HMIS 23.1+23.3:
Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school)
2018-1911.413.617.417.7
HMIS 23.1+23.3:
Percentage of children covered under WIFS JUNIOR (5-9 years) provided 4-5 iron and folic acid (IFA) tablets (In schools + out of school)
2017-189.39.88.26.9
HMIS 23.2+23.4:
Percentage of children (5-9 years) provided albendazole (In schools + out of school)
2020-210.68.22.15.3
HMIS 23.2+23.4:
Percentage of children (5-9 years) provided albendazole (In schools + out of school)
2019-201.28.21.92.9
HMIS 23.2+23.4:
Percentage of children (5-9 years) provided albendazole (In schools + out of school)
2018-192.04.21.12.8
HMIS 23.2+23.4:
Percentage of children (5-9 years) provided albendazole (In schools + out of school)
2017-181.02.90.61.3
Adolescents 10-19 years


Year       Q1       Q2       Q3       Q4
HMIS 22.1.1:
Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2020-2115.424.625.224.6
HMIS 22.1.1:
Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2019-2034.442.942.623.2
HMIS 22.1.1:
Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2018-1927.527.228.826.7
HMIS 22.1.1:
Percentage of (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2017-1821.324.821.519.5
HMIS 22.1.3:
Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres
2020-2120.930.026.116.2
HMIS 22.1.3:
Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres
2019-2021.523.725.114.7
HMIS 22.1.3:
Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres
2018-1913.012.011.111.4
HMIS 22.1.3:
Percentage of out of school adolescent girls 10-19 years provided 4 Iron and Folic Acid (IFA) tablets at Anganwadi Centres
2017-187.77.47.06.5
HMIS 22.1.2:
Percentage of (6-12 class) provided Albendazole in schools
2020-211.915.22.66.4
HMIS 22.1.2:
Percentage of (6-12 class) provided Albendazole in schools
2019-202.710.13.83.2
HMIS 22.1.2:
Percentage of (6-12 class) provided Albendazole in schools
2018-191.86.21.52.7
HMIS 22.1.2:
Percentage of (6-12 class) provided Albendazole in schools
2017-182.24.51.41.7
HMIS 22.1.4:
Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres
2020-212.725.64.512.5
HMIS 22.1.4:
Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres
2019-201.86.81.71.7
HMIS 22.1.4:
Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres
2018-191.55.01.32.3
HMIS 22.1.4:
Percentage of out of school adolescent girls 10-19 years provided Albendazole at Anganwadi Centres
2017-180.91.20.71.8
HMIS 22.1.1.a:
Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2020-2115.924.625.925.3
HMIS 22.1.1.a:
Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2019-2034.543.142.723.0
HMIS 22.1.1.a:
Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2018-1929.128.429.928.0
HMIS 22.1.1.a:
Percentage of girls (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2017-1821.525.622.220.9
HMIS 22.1.1.b:
Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2020-2114.824.624.523.9
HMIS 22.1.1.b:
Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2019-2034.442.742.423.3
HMIS 22.1.1.b:
Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2018-1925.525.627.425.0
HMIS 22.1.1.b:
Percentage of boys (6-12 class) provided 4 Iron and Folic Acid (IFA) tablets in schools
2017-1821.124.020.918.2
HMIS 22.1.2.a:
Percentage of girls (6-12 class) provided Albendazole in schools
2020-212.014.82.66.4
HMIS 22.1.2.a:
Percentage of girls (6-12 class) provided Albendazole in schools
2019-202.610.03.83.8
HMIS 22.1.2.a:
Percentage of girls (6-12 class) provided Albendazole in schools
2018-191.96.31.72.7
HMIS 22.1.2.a:
Percentage of girls (6-12 class) provided Albendazole in schools
2017-182.34.51.41.8
HMIS 22.1.2.b:
Percentage of boys (6-12 class) provided Albendazole in schools
2020-211.715.62.56.5
HMIS 22.1.2.b:
Percentage of boys (6-12 class) provided Albendazole in schools
2019-202.710.23.72.6
HMIS 22.1.2.b:
Percentage of boys (6-12 class) provided Albendazole in schools
2018-191.66.11.42.8
HMIS 22.1.2.b:
Percentage of boys (6-12 class) provided Albendazole in schools
2017-182.14.51.41.7
Pregnant Women


Year       Q1       Q2       Q3       Q4
HMIS 1.2.4:
Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets (Registered Pregnancy)
2020-2188.794.995.093.7
HMIS 1.2.4:
Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets (Registered Pregnancy)
2019-2087.191.792.494.9
HMIS 1.2.4:
Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets (Registered Pregnancy)
2018-1984.186.886.992.1
HMIS 1.2.4:
Percentage of pregnant women (PW) given 180 Iron and Folic Acid (IFA) tablets (Registered Pregnancy)
2017-1874.377.682.783.4
HMIS 1.2.6:
Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester
2020-2147.049.250.148.9
HMIS 1.2.6:
Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester
2019-2040.944.845.847.1
HMIS 1.2.6:
Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester
2018-1935.937.040.838.1
HMIS 1.2.6:
Percentage of pregnant women (PW) given one Albendazole tablet after 1st trimester
2017-1826.830.432.532.2
HMIS 1.4.2:
Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9)
2020-2161.965.568.065.5
HMIS 1.4.2:
Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9)
2019-2068.374.672.669.8
HMIS 1.4.2:
Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9)
2018-1979.970.674.067.1
HMIS 1.4.2:
Percentage of pregnant women (PW) having Hb level<11 (tested cases)(7.1 to 10.9)
2017-1865.369.168.365.3
HMIS 1.4.3:
Percentage of pregnant women (PW) having Hb level<7 (tested cases)
2020-213.13.23.23.2
HMIS 1.4.3:
Percentage of pregnant women (PW) having Hb level<7 (tested cases)
2019-203.53.93.83.4
HMIS 1.4.3:
Percentage of pregnant women (PW) having Hb level<7 (tested cases)
2018-193.53.83.83.5
HMIS 1.4.3:
Percentage of pregnant women (PW) having Hb level<7 (tested cases)
2017-183.44.13.53.5
HMIS 1.4.4:
Percentage of pregnant women (PW) having severe anemia (Hb<7) treated
2020-211.92.02.01.9
HMIS 1.4.4:
Percentage of pregnant women (PW) having severe anemia (Hb<7) treated
2019-202.22.32.01.9
HMIS 1.4.4:
Percentage of pregnant women (PW) having severe anemia (Hb<7) treated
2018-191.92.02.21.8
HMIS 1.4.4:
Percentage of pregnant women (PW) having severe anemia (Hb<7) treated
2017-181.61.91.61.6
Lactating Women 0-6 months


Year       Q1       Q2       Q3       Q4
HMIS 6.3:
Number of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery
2020-2146.057.658.353.7
HMIS 6.3:
Number of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery
2019-2045.053.553.149.2
HMIS 6.3:
Number of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery
2018-1936.545.344.146.1
HMIS 6.3:
Number of mothers provided full course of 180 Iron and Folic Acid (IFA) tablets after delivery
2017-1830.738.838.537.8

Stock Availability

Stocks Available


Year       Q1       Q2       Q3       Q4
HMIS 19.9:
Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric)
2020-2145.846.236.842.3
HMIS 19.9:
Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric)
2019-2049.448.949.857.7
HMIS 19.9:
Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric)
2018-1936.873.449.449.1
HMIS 19.9:
Percentage of stocks available for Iron and Folic Acid (IFA) - Syrup (Paediatric)
2017-1823.636.733.425.8
HMIS 19.6:
Number of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult)
2020-2123.331.030.630.2
HMIS 19.6:
Number of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult)
2019-2034.331.529.919.6
HMIS 19.6:
Number of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult)
2018-1923.728.231.124.5
HMIS 19.6:
Number of stocks available for Iron and Folic Acid (IFA) tablets - Red (Adult)
2017-1814.135.626.223.8
HMIS 19.7:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years)
2020-2143.646.741.037.4
HMIS 19.7:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years)
2019-2047.056.056.134.5
HMIS 19.7:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years)
2018-1958.051.440.031.2
HMIS 19.7:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Blue (Adolescent 10-19 years)
2017-1838.724.332.244.9
HMIS 19.8:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years)
2020-2152.088.448.142.1
HMIS 19.8:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years)
2019-2062.574.666.644.8
HMIS 19.8:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years)
2018-1958.339.441.852.4
HMIS 19.8:
Percentage of stocks available for Iron and Folic Acid (IFA) tablets - Pink (Junior 6-10 years)
2017-1814.514.518.746.1
HMIS 19.15:
Number of stocks available for Albendazole tablets
2020-2154.062.590.264.5
HMIS 19.15:
Number of stocks available for Albendazole tablets
2019-2014.319.53.09.9
HMIS 19.15:
Number of stocks available for Albendazole tablets
2019-2095.064.157.936.5
HMIS 19.15:
Number of stocks available for Albendazole tablets
2018-1921.020.513.611.6
HMIS 19.15:
Number of stocks available for Albendazole tablets
2018-1992.387.267.078.8
HMIS 19.15:
Number of stocks available for Albendazole tablets
2017-184.614.25.828.1
HMIS 19.15:
Number of stocks available for Albendazole tablets
2017-1828.230.262.256.2
Reporting Status


Year       Q1       Q2       Q3       Q4
HMIS A.1:
Percentage of facilities reporting in the quarter
2019-2095.095.095.095.0
HMIS A.1:
Percentage of facilities reporting in the quarter
2018-1995.095.095.095.0
HMIS A.1:
Percentage of facilities reporting in the quarter
2017-1895.095.095.095.0